Phuturdex › Diseases › Diffuse large B-cell lymphoma
Drugs in development · updated 30 October 2026
Diffuse large B-cell lymphoma: drugs in development
As of 30 October 2026 there are 278 active clinical trials (recruiting or ongoing, phases I–III) on 177 drugs for diffuse large B-cell lymphoma. 93 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 93 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RituximabRuxience, Rituxan | II–III | 76 | NCT04799275 |
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 72 | NCT04799275 |
| PrednisonePredinisone, Cortancyl | II–III | 42 | NCT04799275 |
| DoxorubicinAdriamycin, Doxorubincin | II–III | 40 | NCT04799275 |
| LenalidomideRevlimid, lenalinomide | III | 37 | NCT05429268 |
| VincristineVincristin, Oncovin [vincristine] | II–III | 29 | NCT04799275 |
| Polatuzumab VedotinPolivy® | III | 27 | NCT06522555 |
| EpcoritamabEpkinly®, Tepkinly® | III | 24 | NCT05578976 |
| GemcitabineGemcitabin, Gemzar | II–III | 22 | NCT05139017 |
| GlofitamabColumvi® | III | 22 | NCT04408638 |
| OxaliplatinOxaliplatine, Oxaliplain | II–III | 21 | NCT05139017 |
| EtoposideAvopef®, Etopophos Preservative Free® | II–III | 19 | NCT03984448 |
| ZanubrutinibBGB-3111, Brukinsa® | III | 19 | NCT06522555 |
| ObinutuzumabGazyva®, Gazyvaro® | III | 15 | NCT04408638 |
| AcalabrutinibACP-196, Calquence® | III | 13 | NCT04529772 |
Sorted by most advanced phase and number of active trials. Showing 15 of 84 drugs.
All 177 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Plasmablastic lymphoma 19 drugs
- Non-Hodgkin lymphoma 269 drugs
- Burkitt lymphoma 113 drugs
- Follicular lymphoma 144 drugs
- Mantle cell lymphoma 108 drugs
- Lymphoma 252 drugs
- HIV infection 84 drugs
- T-cell lymphoma 74 drugs
- Hodgkin lymphoma 93 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
- Primary effusion lymphoma 13 drugs
Broader categories
- Immunoproliferative disorder 16 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Lymphatic system disease 20 drugs
- Neoplasm 671 drugs
- Lymphoma 252 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016403 “Lymphoma, Large B-Cell, Diffuse”. Prevalence: Orphanet.